1. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22–26.
2. Sánchez-Quijano A, Jauregui JI, Leal M, et al. Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol 1993;17:288–293.
3. Chemin I, Trépo C. Clinical impact of occult HBV infections. J Clin Virol 2005;34(Suppl 1):S15–S21.
4. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479–486.
5. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004;126:102–110.
6. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447–449.
7. Degos F, Lugassy C, Degott C, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients: a prospective study of 90 patients. Gastroenterology 1988;94:151–156.
8. Yoshiba M, Sekiyama K, Sugata F, Kawamoto Y, Muraoka H, Aoyama M. Post-transfusion fulminant hepatitis B after screening for hepatitis B virus core antibody. Lancet 1992;339:253–254.
9. Larsen J, Hetland G, Skaug K. Posttransfusion hepatitis B transmitted by blood from a hepatitis B surface antigennegative hepatitis B virus carrier. Transfusion 1990;30:431–432.
10. Fabrizi F, Messa PG, Lunghi G, et al. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005;21:1341–1347.
11. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004;39:51–57.
12. Toyoda H, Hayashi K, Murakami Y, et al. Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol 2004;73:195–199.
13. Mrani S, Chemin I, Menouar K, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 2007;79:1075–1081.
14. Fukuda R, Ishimura N, Niigaki M, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58:201–207.
15. Sagnelli E, Imparato M, Coppola N, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol 2008;80:1547–1553.
16. Fabris P, Brown D, Tositti G, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004;29:160–166.
17. Levast M, Larrat S, Thelu MA, et al. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin. J Med Virol 2010;82:747–754.
18. Park YN, Kim HG, Chon CY, et al. Histological grading and staging of chronic hepatitis standardized guideline proposed by the Korean Study Group for the Pathology of Digestive Diseases. Korean J Pathol 1999;33:337–346.
19. The Korean Association for The Study of 2004 KASL guideline for management of hepatitis C. Korean J Hepatol 2004;10(Suppl):101S–125S.
20. Song EY, Yun YM, Park MH, Seo DH. Prevalence of occult hepatitis B virus infection in a general adult population in Korea. Intervirology 2009;52:57–62.
21. Lee HS, Yoon JH, Kim W, Kim CY. Relativve etiologic role of hepatitis B virus and hepatitis C virus in HBsAg-negative patients with chronic liver disease in Korea: determination of serum HBV DNA using polymerase chain reaction and of serum anti-HCV using ELISA. Korean J Med 1992;42:8–15.
22. Kim YS, Jang JY, Eun SH, et al. Detection of intrahepatic HBV DNA in HBsAg-negative liver diseases. Korean J Hepatol 2006;12:201–208.
23. Kwon CH, Suh KS, Cho JY, Yi NJ, Jang JJ, Lee KU. Change of hepatitis B virus DNA status in anti-HBc positive liver graft. Korean J Hepatol 2006;12:191–200.
25. Kim SM, Lee KS, Park CJ, et al. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 2007;54:185–191.
27. Jilg W, Sieger E, Zachoval R, Schätzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995;23:14–20.